These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37592424)

  • 1. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
    Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
    Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
    Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
    Desmoulin F; Gilard V; Malet-Martino M; Martino R
    Drug Metab Dispos; 2002 Nov; 30(11):1221-9. PubMed ID: 12386128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of the major metabolites of capecitabine.
    Gieschke R; Reigner B; Blesch KS; Steimer JL
    J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
    Dhananjeyan MR; Liu J; Bykowski C; Trendel JA; Sarver JG; Ando H; Erhardt PW
    J Chromatogr A; 2007 Jan; 1138(1-2):101-8. PubMed ID: 17070825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
    Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
    Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
    Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS.
    Radovanovic M; Schneider JJ; Shafiei M; Martin JH; Galettis P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Jan; 1188():123075. PubMed ID: 34891049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.
    Inaishi T; Fujita KI; Matsumoto N; Shimokata T; Maeda O; Kikumori T; Hattori N; Nakayama G; Ando Y
    In Vivo; 2020; 34(6):3539-3544. PubMed ID: 33144465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
    Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
    Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
    Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma.
    Licea-Perez H; Wang S; Bowen C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(11-12):1040-6. PubMed ID: 19285927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
    Jacobs BA; Rosing H; de Vries N; Meulendijks D; Henricks LM; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2016 Jul; 126():75-82. PubMed ID: 27179185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.
    Buchner P; Mihola E; Sahmanovic A; Steininger T; Dittrich C; Czejka M
    Anticancer Res; 2013 Mar; 33(3):881-6. PubMed ID: 23482757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
    Urien S; Rezaí K; Lokiec F
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.